Cell and gene therapy companies have been rapidly populating over the past few years, making the cell therapy market a high-value, fast-growth market. Key drivers for the market include high rates of cell therapy clinical trials, accelerated pathways for cell therapy product approvals, new technologies to support cell therapy manufacturing, and the potential for cell therapies to revolutionize healthcare.
The market gained additional momentum when the Swiss pharmaceutical giant Novartis made history as the first company to win FDA approval for a CAR-T cell therapy in the U.S. in August 2017 (Kymriah). In October 2017, Kite Pharma became the second company to get FDA approval of a CAR-T cell therapy (Yescarta).
These historic events demonstrate to investors, the public and funding providers alike that the cell and gene therapy is a market that has emerged, no longer one that is evolving in the future.
With accelerating momentum fueling the industry, BioInformant honored to announce that we are a sponsor for Phacilitate’s Cell and Gene Therapy World in Miami, Florida on January 22-25, 2018.
What Is Cell and Gene Therapy World?
Hosted by Phacilitate, the event reflects the dynamic growth of the cell and gene therapy industry. It will showcase small and large companies, investors, and regulators and facilitate strategic knowledge exchange and networking.
Focused on solutions to support R&D, accelerate clinical progress, and break through manufacturing bottlenecks, attendees will learn from key voices that are defining commercial success for cell and gene therapy products.
With 25+ hours of networking, 350+ organizations, 850+ attendees, and 200+ speakers from across the globe, the event provides extensive opportunities for collaboration and networking.
Cord Blood and Perinatal Stem Cell Track
Because this conference is the only event to showcase the global cord blood and perinatal stem cell field, while acknowledging it as a critically important component of the broader cell and gene therapy field, our President, Cade Hildreth, is honored to be Chairing the Cord Blood and Perinatal Stem Cell Track.
Shared between the Cell & Gene Therapy World and World Stem Cell Summit agendas, the two-day Cord Blood and Perinatal Stem Cell Track will provide insight on business models and financing opportunities, as well as scientific and technical updates on clinical applications and cell expansion approaches.
Endorsed by the Cord Blood Association and BioInformant, the Cord Blood & Perinatal Stem Cell track is a must-attend series for those invested in realizing the potential of this burgeoning sector.
10% Off with the Code “BIO10“
Because we would love to meet you in person, we have secured a deal for BioInformant readers to get 10% off your pass with the code “BIO10“.
Use it during registration to lock in your free savings. Event details are below:
Phacilitate’s Cell & Gene Therapy World
January 22-25, 2017
If you are already registered, email us at Info@BioInformant.com and let’s meet up there!